Nocturnal activity with nighttime pergolide in Parkinson disease: a controlled study using actigraphy.
Pergolide is a dopamine agonist that improves Parkinson disease but is associated with dose-dependent sleepiness. This study evaluates the effect of a nighttime dose of 1 mg of pergolide on actigraphic measures of sleep using a randomized, double-blind, placebo-controlled study design. The pergolide group (n = 10) worsened in actigraphic measures of sleep efficiency and sleep fragmentation vs the placebo group (n = 12). Side effects were more frequent in the pergolide group.
Comella
Cynthia L
CL
Department of Neurologic Sciences, Rush University Medical Center, 1725 W. Harrison, Chicago, IL 60612, USA. ccomella@rush.edu
Morrissey
Mary
M
Janko
Kimberly
K
D000367:Age Factors; D000368:Aged; D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000009:adverse effects; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D002940:Circadian Rhythm / Q000187:drug effects / Q000502:physiology; D003248:Constipation / Q000139:chemically induced; D004244:Dizziness / Q000139:chemically induced; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000009:adverse effects*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D010300:Parkinson Disease / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology; D010479:Pergolide / Q000008:administration & dosage / Q000009:adverse effects*; D010919:Placebos; D012737:Sex Factors; D012890:Sleep / Q000187:drug effects / Q000502:physiology; D012893:Sleep Wake Disorders / Q000139:chemically induced / Q000175:diagnosis / Q000209:etiology*; D016896:Treatment Outcome
D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D010919:Placebos; D010479:Pergolide; D007980:Levodopa